




Janssen's Journey Towards a Culture of Innovation

PhUSE EU connect - 2019

Sumesh Kalappurakal
Head, Analytics Innovation

Lisa Lyons
DM Head, Central Services

Hepatitis B virus

Sangeeta Bhattacharya
TA Head Immunology

Marion Wolfs
Head, Risk Management Central Monitoring

Disclaimer



The presentation is intended for educational purpose only and does not replace independent professional Judgement. Statements of fact and opinions expressed are those of the participant individually and, unless expressly stated to the contrary, are not the opinion or position of Janssen Pharmaceutical Research and Development.

Acknowledgement

We would like to thank the following individuals for their encouragement, guidance and support on this journey.



Darren Weston
(VP IDAR GCDO)



Olivier Leconte
(Global Head Statistical Programming & Analysis)



Samar Noor
(Global Head DATA Management &
Clinical Standards Development)



Neil Garrett
(Global Head Regulatory Medical Writing)

Also extending our sincere thanks to **Frank Meloni** (Director, RMW), **Stephen Bamford** (Head, IDAR Data Transparency), **Tammy Guld** (Sr. Director, Janssen Clinical Innovation) and **Paul Hilton** (IDAR Therapeutic Area Lead) for their great insights and contributions to the paper and presentation.

Finally thanks to our PhUSE EU connect 2019 Leadership & Innovation Stream Chairs
(**Leanne, Jasmine and Gary**)

Agenda

1 Introduction to Innovation

2 Overview of IDAR

3 Innovative approaches

4 Challenges and Roadblocks

5 Building Innovative culture


6 Conclusion

7 Q&A

Introduction to Innovation



Introduction to Innovation



"Innovation is a way to share ideas and creativity, sourcing from every single talent in the company"

Overview of IDAR



Integrated Data Analytics and Reporting

Data Transparency



IDAR Therapeutic Area Leads

Statistical Programming & Analysis



Janssen Clinical Innovation

“Converting data into knowledge in order to support the best possible data-driven decisions”

Risk Management
&
Central Monitoring



Data Management
&
Clinical Development Standards

Regulatory Medical Writing




Business Operations

Innovative approaches



Innovative approaches to Data Collection

Clinical Trials: Moving to era of continuous electronic data collection utilizing devices and techniques



- This has a disruptive impact on the way we manage our clinical trials and requires the need to manage risks.
- As **leaders** we need to provide strategic vision to our teams, create a culture that embraces change..... help connect the “dots” and prepare for this digital transformation.
- Within **IDAR** we are leading our teams to drive value through standardization, innovation and technology

Integrated Smart Trial Engagement Program (iSTEP)

Site Kit Tracking

Track supply activities
via medication
scanners

Patient App

Personalized patient
support & data
collection

Smart Blister


Chip enabled
medication packages
tracks pill dispensing



Innovation of Automated Data Flow





Our strategic roadmap includes metadata driven automated data flow



*Data Review Model (DRM))

Next Generation Risk Management and Central Monitoring

A shift from reactive, rigid, manual and subjective to predictive, agile, automated and data driven




Data wrangling and analytics support for Innovative Approaches – Novel Biomarker



RNA Seq



Clinical Study Data



Cluster Analysis



Collaborating with external companies

Innovative Approaches de-identification

DICOM – Digital Imaging and Communications in Medicine



Metadata
Extraction




(0002,0000)	UL	1	4	File Meta Information Group Length	210
(0002,0001)	OB	1	2	File Meta Information Version	01 00
(0002,0002)	UT	1	26	Media Storage SOP Class UID	1.2.840.10008.5.1.4.1.1.7
(0002,0003)	UT	1	56	Media Storage SOP Instance UID	1.3.6.1.4.1.22272.411956558537253486083209268270
(0002,0010)	UT	1	18	Transfer Syntax UID	Implicit VR Little Endian [1.2.840.10008.1.2]
(0002,0012)	UT	1	20	Implementation Class UID	1.2.826.0.1.3680043
(0002,0013)	SH	1	18	Implementation Version Name	MD DCM4CHE3 Win32
(0002,0016)	UT	1	10	Source Application Entity Title	
(0008,0005)	CS	1	10	Specific Character Set	ISO_IR 100
(0008,0008)	CS	4	34	Image Type	
(0008,0012)	DA	1	8	Instance Creation Date	00010101
(0008,0013)	TM	1	10	Instance Creation Time	154040.871
(0008,0016)	UT	1	26	SOP Class UID	1.2.840.10008.5.1.4.1.1.2
(0008,0018)	UT	1	18	SOP Instance UID	1.2.826.0.1.26781
(0008,0020)	DA	1	8	Study Date	00010101
(0008,0021)	DA	1	8	Series Date	00010101
(0008,0022)	DA	1	8	Acquisition Date	00010101
(0008,0023)	DA	1	8	Content Date	00010101
(0008,0025)	DA	1	8		
(0008,0030)	TM	1	14	Study Time	155621.703000
(0008,0031)	TM	1	14	Series Time	160643.812000

Example metadata



Metadata
Review



New ID
mapping &
Strategy



Anonymization




De-identified
CT scans




Innovative Approach Direct-to-Patient Trial Model Overview

- Conventional model:



- Direct-to-patient model:



Graphic courtesy of Science 37

Challenges & Roadblocks




Challenges and Roadblocks

“Unknown and unseen dots can make many people and enterprises uncomfortable”



that's not the way we do things



time / resource/ budget




Innovative Culture



Innovative Culture

To keep our vision and innovations alive



Enable employees to adopt an "**entrepreneurial mindset**" to showcase their ideas and they become the foundation for organizational growth and sustainability, allowing employees to propel innovation and show initiative is the key to success.

Conclusion



Conclusion

We as leaders, need to be energized in a manner that inspires hope and evolution in order to propel innovative opportunities for growth, prosperity and sustainability.

“Innovation is the difference between a leader and a follower.”

Steve Jobs

A black and white image of a handwritten signature that reads "Steven jobs". The signature is written in a cursive, lowercase style.

Q&A

